These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 39261670)
1. Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epithelium. Paull JRA; Luscombe CA; Seta A; Heery GP; Bobardt MD; Gallay PA; Constant S; Castellarnau A Sci Rep; 2024 Sep; 14(1):21259. PubMed ID: 39261670 [TBL] [Abstract][Full Text] [Related]
2. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice. Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519 [TBL] [Abstract][Full Text] [Related]
3. Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial. Castellarnau A; Heery GP; Seta A; Luscombe CA; Kinghorn GR; Button P; McCloud P; Paull JRA Sci Rep; 2022 Jun; 12(1):10210. PubMed ID: 35715644 [TBL] [Abstract][Full Text] [Related]
4. Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia. Fais F; Juskeviciene R; Francardo V; Mateos S; Guyard M; Viollet C; Constant S; Borelli M; Hohenfeld IP Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409423 [TBL] [Abstract][Full Text] [Related]
7. Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures. Schütz D; Conzelmann C; Fois G; Groß R; Weil T; Wettstein L; Stenger S; Zelikin A; Hoffmann TK; Frick M; Müller JA; Münch J Am J Physiol Lung Cell Mol Physiol; 2021 May; 320(5):L750-L756. PubMed ID: 33561380 [TBL] [Abstract][Full Text] [Related]
8. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro. Paull JRA; Heery GP; Bobardt MD; Castellarnau A; Luscombe CA; Fairley JK; Gallay PA Antiviral Res; 2021 Jul; 191():105089. PubMed ID: 34010661 [TBL] [Abstract][Full Text] [Related]
9. Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial. Winchester S; Castellarnau A; Jabbar K; Nadir M; Ranasinghe K; Masramon X; Kinghorn GR; John I; Paull JRA Pharmaceutics; 2024 Sep; 16(9):. PubMed ID: 39339209 [TBL] [Abstract][Full Text] [Related]
10. Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture. Bansal S; Jonsson CB; Taylor SL; Figueroa JM; Dugour AV; Palacios C; Vega JC PLoS One; 2021; 16(11):e0259943. PubMed ID: 34797868 [TBL] [Abstract][Full Text] [Related]
11. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. Fazekas T; Eickhoff P; Pruckner N; Vollnhofer G; Fischmeister G; Diakos C; Rauch M; Verdianz M; Zoubek A; Gadner H; Lion T BMC Complement Altern Med; 2012 Sep; 12():147. PubMed ID: 22950667 [TBL] [Abstract][Full Text] [Related]
12. Natural Derived Nasal Spray; A Proposed Approach for COVID-19 Disease Control. Hoseini-Tavassol Z; Ejtahed HS; Soroush AR; Sajjadpour Z; Hasani-Ranjbar S; Larijani B Infect Disord Drug Targets; 2021; 21(8):e160921191568. PubMed ID: 33602078 [TBL] [Abstract][Full Text] [Related]
13. Iota-carrageenan extracted from red algae is a potent inhibitor of SARS-CoV-2 infection in reconstituted human airway epithelia. Bovard D; van der Toorn M; Schlage WK; Constant S; Renggli K; Peitsch MC; Hoeng J Biochem Biophys Rep; 2022 Mar; 29():101187. PubMed ID: 34931176 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo effects of ribavirin on human respiratory epithelium. Han LY; Wilson R; Slater S; Rutman A; Read RC; Snell NJ; Cole PJ Thorax; 1990 Feb; 45(2):100-4. PubMed ID: 2315872 [TBL] [Abstract][Full Text] [Related]
15. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro. Morokutti-Kurz M; Fröba M; Graf P; Große M; Grassauer A; Auth J; Schubert U; Prieschl-Grassauer E PLoS One; 2021; 16(2):e0237480. PubMed ID: 33596218 [TBL] [Abstract][Full Text] [Related]
16. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial. Hasan MJ; Rumi SKNF; Banu SS; Uddin AKMN; Islam MS; Arefin MK Trials; 2021 Jan; 22(1):2. PubMed ID: 33397432 [TBL] [Abstract][Full Text] [Related]
17. Antiviral Potential of Azelastine against Major Respiratory Viruses. Fischhuber K; Bánki Z; Kimpel J; Kragl N; Rössler A; Bolze A; Muellauer B; Angerer J; Nagy G; Nagy E; Szijarto V Viruses; 2023 Nov; 15(12):. PubMed ID: 38140540 [TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2. Friedland PL; Tucker S Laryngoscope; 2024 Sep; 134(9):3947-3952. PubMed ID: 38554057 [TBL] [Abstract][Full Text] [Related]
19. Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Sisson JH; Yonkers AJ; Waldman RH Chest; 1995 Mar; 107(3):747-51. PubMed ID: 7874947 [TBL] [Abstract][Full Text] [Related]
20. Review of the use of nasal and oral antiseptics during a global pandemic. Stathis C; Victoria N; Loomis K; Nguyen SA; Eggers M; Septimus E; Safdar N Future Microbiol; 2021 Jan; 16(2):119-130. PubMed ID: 33464122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]